US 9550994
RNAI-mediated inhibition of frizzled related protein-1 for treatment of glaucoma
granted A61KA61K31/7088A61K31/713
Quick answer
US patent 9550994 (RNAI-mediated inhibition of frizzled related protein-1 for treatment of glaucoma) held by Arrowhead Pharmaceuticals, Inc. expires Mon Jan 19 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Arrowhead Pharmaceuticals, Inc.
- Grant date
- Tue Jan 24 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jan 19 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 8
- CPC classes
- A61K, A61K31/7088, A61K31/713, A61K38/00, A61K48/00